Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, April 20, 2023
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
[ Thu, Apr 20th 2023
] - WOPRAI
Serge Belanger Reiterated (BCRX) at Strong Buy and Held Target at $14 on, Apr 20th, 2023
Serge Belanger of Needham, Reiterated "BioCryst Pharmaceuticals, Inc." (BCRX) at Strong Buy and Held Target at $14 on, Apr 20th, 2023.
Serge has made no other calls on BCRX in the last 4 months.
There are 3 other peers that have a rating on BCRX. Out of the 3 peers that are also analyzing BCRX, 1 agrees with Serge's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Reiterated at Hold and Held Target at $10 on, Tuesday, March 14th, 2023
These are the ratings of the 2 analyists that currently disagree with Serge
- Jonathan Wolleben of "JMP Securities" Reiterated at Buy and Held Target at $16 on, Wednesday, February 22nd, 2023
- Andrew Fein of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $30 on, Wednesday, February 22nd, 2023
